A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.

被引：4
|
作者：
Dalgleish, Angus George [1 ]
机构：
[1] St Georges Univ London, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.336
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
336
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
    Dalgleish, Angus G.
    Stebbing, Justin
    Adamson, Douglas J. A.
    Arif, Seema Safia
    Bidoli, Paolo
    Chang, David
    Cheeseman, Sue
    Diaz-Beveridge, Robert
    Fernandez-Martos, Carlos
    Glynne-Jones, Rob
    Granetto, Cristina
    Massuti, Bartomeu
    McAdam, Karen
    McDermott, Raymond
    Munoz Martin, Andres J.
    Papamichael, Demetris
    Pazo-Cid, Roberto
    Vieitez, Jose M.
    Zaniboni, Alberto
    Carroll, Kevin J.
    Wagle, Shama
    Gaya, Andrew
    Mudan, Satvinder S.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (07) : 789 - 796
  • [2] Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
    Angus G Dalgleish
    Justin Stebbing
    Douglas JA Adamson
    Seema Safia Arif
    Paolo Bidoli
    David Chang
    Sue Cheeseman
    Robert Diaz-Beveridge
    Carlos Fernandez-Martos
    Rob Glynne-Jones
    Cristina Granetto
    Bartomeu Massuti
    Karen McAdam
    Raymond McDermott
    Andrés J Muñoz Martín
    Demetris Papamichael
    Roberto Pazo-Cid
    Jose M Vieitez
    Alberto Zaniboni
    Kevin J Carroll
    Shama Wagle
    Andrew Gaya
    Satvinder S Mudan
    [J]. British Journal of Cancer, 2016, 115 : 789 - 796
  • [3] Erratum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
    Angus G Dalgleish
    Justin Stebbing
    Douglas J A Adamson
    Seema Safia Arif
    Paolo Bidoli
    David Chang
    Sue Cheeseman
    Robert Diaz-Beveridge
    Carlos Fernandez-Martos
    Rob Glynne-Jones
    Cristina Granetto
    Bartomeu Massuti
    Karen McAdam
    Raymond McDermott
    Andrés J Muñoz Martín
    Demetris Papamichael
    Roberto Pazo-Cid
    Jose M Vieitez
    Alberto Zaniboni
    Kevin J Carroll
    Shama Wagle
    Andrew Gaya
    Satvinder S Mudan
    [J]. British Journal of Cancer, 2016, 115 : e16 - e16
  • [4] Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.
    Dalgleish, Angus George
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (vol 115, pg 789, 2016)
    Dalgleish, Angus G.
    Stebbing, Justin
    Adamson, Douglas J. A.
    Arif, Seema Safia
    Bidoli, Paolo
    Chang, David
    Cheeseman, Sue
    Diaz-Beveridge, Robert
    Fernandez-Martos, Carlos
    Glynne-Jones, Rob
    Granetto, Cristina
    Massuti, Bartomeu
    McAdam, Karen
    McDermott, Raymond
    Munoz Martin, Andres J.
    Papamichael, Demetris
    Pazo-Cid, Roberto
    Vieitez, Jose M.
    Zaniboni, Alberto
    Carroll, Kevin J.
    Wagle, Shama
    Gaya, Andrew
    Mudan, Satvinder S.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (09) : E16 - E16
  • [6] Baseline carcinoembryonic antigen predicts response to IMM-101 in advanced pancreatic cancer: Data analysis from a randomised, open label, phase II study
    Laura, Rosa Brunet
    Kevin, Carroll
    Linda, Summerton
    Shama, Wagle
    Michel, Ducreux
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [7] Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer.
    Albain, K
    Elledge, R
    Gradishar, WJ
    Hayes, DF
    Rowinsky, E
    Hudis, C
    Pusztai, L
    Tripathy, D
    Modi, S
    Rubi, S
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S33 - S33
  • [8] Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma.
    Pandya, Shuchi Sumant
    Wong, Lucas
    Bullock, Andrea J.
    Grabelsky, Stephen A.
    Shum, Merrill Kingman
    Shan, Joseph
    Menander, Kerstin B.
    Reid, Tony R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.
    Moehler, M. H.
    Hartmann, J. T.
    Lordick, F.
    Al-Batran, S.
    Reimer, P.
    Trarbach, T.
    Ebert, M. P.
    Daum, S.
    Weihrauch, M.
    Galle, P. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial
    Christensen, Jeppe Romme
    Ratzer, Rikke
    Bornsen, Lars
    Lyksborg, Mark
    Garde, Ellen
    Dyrby, Tim B.
    Siebner, Hartwig R.
    Sorensen, Per S.
    Sellebjerg, Finn
    [J]. NEUROLOGY, 2014, 82 (17) : 1499 - 1507
12345